All In Biotech

Drug Trial Radar · NCT06647745

A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 222 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

222

Actual

Start

Apr 10, 2025

Primary completion

Nov 4, 2026

Study completion Jan 28, 2027

Sponsor

Lead sponsor
THPharm Corp.Industry
Sponsor type
Industry
First posted
Oct 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

\[Primary Objective\] To demonstrate the superiority of the change in mean sitting systolic blood pressure (MSSBP) and hemoglobin A1c (HbA1c)on week 12 of the combination therapy of THP-00101 (dapagliflozin 10 mg) and THP-00102 (telmisartan 80 mg) compared to THP-00101 or THP-00102 monotherapy among subjects with type 2 diabetes mellitus accompanied by essential hypertension. \[Secondary Objective\] To comparatively evaluate secondary efficacy and safety in the THP-00101 monotherapy group, THP-00102 monotherapy group, THP-00101 and THP-00102 combination therapy group, and THP-00101 and THP-00103 (telmisartan 40 mg) combination therapy group among subjects with type 2 diabetes mellitus accompanied by essential hypertension.

Conditions

  • Type 2 Diabetes
  • Hypertension

Interventions

  • THP-00101Drug

    Dapagliflozin 10 mg

  • THP-00102Drug

    Telmisartan 80 mg

  • THP-00103Drug

    Telmisartan 40 mg

  • THP-00104Drug

    Placebo of Dapagliflozin 10mg

  • THP-00105Drug

    Placebo of Telmisartan 80mg

  • THP-00106Drug

    Placebo of Telmisartan 40mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in Hemoglobin A1c (HbA1c)Time frame: 12 weeks
  2. Changes in Mean Sitting Systolic Blood Pressure (MSSBP)Time frame: 12 Weeks

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • The Catholic University of Korea, Yeouido ST. Mary's Hospital

    Seoul, South Korea

  • Thammasat University Hospital

    Pathum Thani, Changwat Pathum Thani, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.